Paul Farrington

AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity

Jacqueline H. L. Fok, Antonio Ramos‐Montoya, Mercedes Vázquez–Chantada et al. · Nature Communications · 2019 · 334 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)

Richard A. Ward, Mark J. Anderton, Paul A. Bethel et al. · Journal of Medicinal Chemistry · 2019 · 78 citations · Full text

Medicine, Oncology, Pharmacology +17

Orally Bioavailable and Blood–Brain Barrier-Penetrating ATM Inhibitor (AZ32) Radiosensitizes Intracranial Gliomas in Mice

Jeremy Karlin, Jasmine Allen, Syed Farhan Ahmad et al. · Molecular Cancer Therapeutics · 2018 · 61 citations · Full text

Medicine, Oncology, Pharmacology +16

Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control

Kyoko Nakamura, Ankur Karmokar, Paul Farrington et al. · Clinical Cancer Research · 2021 · 55 citations · Full text

Medicine, Oncology, Radiation Oncology +17

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i> -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib

Vikki Flemington, Emma Jane Davies, David M. Robinson et al. · Molecular Cancer Therapeutics · 2020 · 26 citations

Medicine, Oncology, Pharmacology +17